Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 73

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 73
---
ertide (TAK-121), an investigational injectable hepcidin mimetic peptide of the natural hormone he...  
  Teva Pharmaceutical Industries              Israel                Agreement for worldwide license to multi-target discovery collaboration accessing Teva’s AttenukineTM platform.                                                                                       
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Plasma-Derived Therapies

  Partner                                        Country               Subject                                                                                                                                                                                               
                                                 of incorporation                                                                                                                                                                                                            
  Halozyme                                       U. S.                 Agreement for the in-license of Halozyme’s proprietary ENHANZE™ platform technology to increase dispersion and absorption of HYQVIA.                                                                  
  Kamada                                         Israel                In-license agreement to develop and commercialize IV Alpha-1 proteinase inhibitor (GLASSIA); Exclusive supply and distribution of GLASSIA in the U. S., Canada, Australia and New Zealand; work o...  
  Johnson & Johnson/Momenta Pharmaceuticals      U. S.                 In-licensing agreement with Momenta Pharmaceuticals, Inc. which was acquired by Johnson & Johnson for an investigational hypersialylated immunoglobulin (hsIgG) candidate.                            
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  PreviPharma                                    EU                    Research collaboration and option agreement to develop new targeted proteins                                                                                                                          

Table of Contents

Vaccines

  Partner      Country               Subject                                                                                                                                                                                               
               of incorporation                                                                                                                                                                                                            
  Novavax      U. S.                 Partnership for the development, manufacturing and commercialization of Nuvaxovid Intramuscular Injection, Novavax’s COVID 19 vaccine in Japan, which is being funded by the Government of Japan’...  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Other / Multiple Therapeutic Area

  Partner                                                                Country               Subject                                                                                                                                                                                               
                                                                         of incorporation                                                                                                                                                                                                            
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  BridGene Biosciences                                                   U. S.                 Research collaboration to discover small molecule drugs for “undr